- Home
- JMSB vs BCYC Comparison
JMSB vs BCYC Comparison
Compare JMSB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMSB | BCYC |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United Kingdom |
| Employees | 140 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.2M | 310.7M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JMSB | BCYC |
|---|---|---|
| Price | $21.23 | $4.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $23.00 | $13.90 |
| AVG Volume (30 Days) | 30.0K | ★ 501.2K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 24.17 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.09 | N/A |
| Revenue Next Year | $10.03 | N/A |
| P/E Ratio | $49.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.70 | $3.95 |
| 52 Week High | $22.35 | $9.18 |
Technical Indicators
Market Signals| Indicator | JMSB | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 37.31 |
| Support Level | $20.42 | N/A |
| Resistance Level | $21.40 | $5.31 |
| Average True Range (ATR) | 0.54 | 0.19 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 40.10 | 13.21 |
Price Performance
Historical ComparisonAbout JMSB John Marshall Bancorp Inc.
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.